We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat. Following the completion of our global Phase 3 clinical development program for vadadustat, we have now submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for U.S. regulatory approval for vadadustat for the treatment of anemia due to CKD for adult patients on dialysis and adult patients not on dialysis. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science.

Vadadustat is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for use outside of Japan. Within Japan, vadadustat is approved and marketed by Mitsubishi Tanabe Pharma Corporation under the trade name VAFSEO™ as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.